26080 Search Results


yes plasmid  (ATCC)
90
ATCC yes plasmid
Yes Plasmid, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/yes plasmid/product/ATCC
Average 90 stars, based on 1 article reviews
yes plasmid - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
nbp2-26080  (Bio-Techne corporation)
90
Bio-Techne corporation nbp2-26080
Nbp2 26080, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nbp2-26080/product/Bio-Techne corporation
Average 90 stars, based on 1 article reviews
nbp2-26080 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
bola2b  (Proteintech)
91
Proteintech bola2b
High expression of <t>BOLA2B</t> in cancers. (A) The mRNA expression of BOLA2B across 33 cancer types from TCGA data. (B) The mRNA expression difference from paired cancer and para-cancer in 18 cancer types. (C) The protein expression of BOLA2B from the CPTAC dataset. Red color represents the tumor sample, and blue color refers to normal samples. * p < 0.05, ** p < 0.01, and *** p < 0.001.
Bola2b, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bola2b/product/Proteintech
Average 91 stars, based on 1 article reviews
bola2b - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
imidazole (#26080)  (SERVA Electrophoresis)
90
SERVA Electrophoresis imidazole (#26080)
High expression of <t>BOLA2B</t> in cancers. (A) The mRNA expression of BOLA2B across 33 cancer types from TCGA data. (B) The mRNA expression difference from paired cancer and para-cancer in 18 cancer types. (C) The protein expression of BOLA2B from the CPTAC dataset. Red color represents the tumor sample, and blue color refers to normal samples. * p < 0.05, ** p < 0.01, and *** p < 0.001.
Imidazole (#26080), supplied by SERVA Electrophoresis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/imidazole (#26080)/product/SERVA Electrophoresis
Average 90 stars, based on 1 article reviews
imidazole (#26080) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


High expression of BOLA2B in cancers. (A) The mRNA expression of BOLA2B across 33 cancer types from TCGA data. (B) The mRNA expression difference from paired cancer and para-cancer in 18 cancer types. (C) The protein expression of BOLA2B from the CPTAC dataset. Red color represents the tumor sample, and blue color refers to normal samples. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Journal: Frontiers in Genetics

Article Title: Integrative analysis of the role of BOLA2B in human pan-cancer

doi: 10.3389/fgene.2023.1077126

Figure Lengend Snippet: High expression of BOLA2B in cancers. (A) The mRNA expression of BOLA2B across 33 cancer types from TCGA data. (B) The mRNA expression difference from paired cancer and para-cancer in 18 cancer types. (C) The protein expression of BOLA2B from the CPTAC dataset. Red color represents the tumor sample, and blue color refers to normal samples. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: The antibodies used in the study were against BolA2B (Proteintech, # 26080-1-AP), tubulin (Proteintech, #11224-1-AP), CDK6 (Cell Signaling Technology [CST], #13331), cdc6 (CST, #3387), cyclin B1 (CST, #12231), cyclin D1 (CST, #55506), cyclin E1 (CST, #20808), p21 (CST, #2947), p-AKT (CST, #4060), AKT (CST, #9272), p-mTOR (CST, #5536), mTOR (CST, #2983), p-ERK (CST, #4370), and ERK (CST, #4695).

Techniques: Expressing

Association of BOLA2B with poor overall survival prognosis in cancers. (A) Hazard ratio of BOLA2B expression in different cancers from the TCGA dataset. (B) Representative images of BOLA2B influence on prognosis of NB, GBMLGG, UVM, KIRC, LIHC, KIPAN, LGG, ACC, and OV. The x-axis represents the number of days.

Journal: Frontiers in Genetics

Article Title: Integrative analysis of the role of BOLA2B in human pan-cancer

doi: 10.3389/fgene.2023.1077126

Figure Lengend Snippet: Association of BOLA2B with poor overall survival prognosis in cancers. (A) Hazard ratio of BOLA2B expression in different cancers from the TCGA dataset. (B) Representative images of BOLA2B influence on prognosis of NB, GBMLGG, UVM, KIRC, LIHC, KIPAN, LGG, ACC, and OV. The x-axis represents the number of days.

Article Snippet: The antibodies used in the study were against BolA2B (Proteintech, # 26080-1-AP), tubulin (Proteintech, #11224-1-AP), CDK6 (Cell Signaling Technology [CST], #13331), cdc6 (CST, #3387), cyclin B1 (CST, #12231), cyclin D1 (CST, #55506), cyclin E1 (CST, #20808), p21 (CST, #2947), p-AKT (CST, #4060), AKT (CST, #9272), p-mTOR (CST, #5536), mTOR (CST, #2983), p-ERK (CST, #4370), and ERK (CST, #4695).

Techniques: Expressing

Heatmaps of BOLA2B correlation with mRNA modification. The color depth in the heatmap represented correlation coefficients of BOLA2B and mRNA modification markers. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Journal: Frontiers in Genetics

Article Title: Integrative analysis of the role of BOLA2B in human pan-cancer

doi: 10.3389/fgene.2023.1077126

Figure Lengend Snippet: Heatmaps of BOLA2B correlation with mRNA modification. The color depth in the heatmap represented correlation coefficients of BOLA2B and mRNA modification markers. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: The antibodies used in the study were against BolA2B (Proteintech, # 26080-1-AP), tubulin (Proteintech, #11224-1-AP), CDK6 (Cell Signaling Technology [CST], #13331), cdc6 (CST, #3387), cyclin B1 (CST, #12231), cyclin D1 (CST, #55506), cyclin E1 (CST, #20808), p21 (CST, #2947), p-AKT (CST, #4060), AKT (CST, #9272), p-mTOR (CST, #5536), mTOR (CST, #2983), p-ERK (CST, #4370), and ERK (CST, #4695).

Techniques: Modification

Correlation of BOLA2B expression with immune response. (A) Correlation of BOLA2B with key immune cells in TCGA. (B) Heatmaps of the relationship of stimulatory and inhibitory immune cytokines with BOLA2B across cancers. (C) Representative ESTIMATE evaluation of BOLA2B expression in the top three cancers. (D) The lollipop plot of BOLA2B association with tumor purity in cancers. (E) The lollipop plot of BOLA2B association with tumor mutational burden (TMB) in cancers.

Journal: Frontiers in Genetics

Article Title: Integrative analysis of the role of BOLA2B in human pan-cancer

doi: 10.3389/fgene.2023.1077126

Figure Lengend Snippet: Correlation of BOLA2B expression with immune response. (A) Correlation of BOLA2B with key immune cells in TCGA. (B) Heatmaps of the relationship of stimulatory and inhibitory immune cytokines with BOLA2B across cancers. (C) Representative ESTIMATE evaluation of BOLA2B expression in the top three cancers. (D) The lollipop plot of BOLA2B association with tumor purity in cancers. (E) The lollipop plot of BOLA2B association with tumor mutational burden (TMB) in cancers.

Article Snippet: The antibodies used in the study were against BolA2B (Proteintech, # 26080-1-AP), tubulin (Proteintech, #11224-1-AP), CDK6 (Cell Signaling Technology [CST], #13331), cdc6 (CST, #3387), cyclin B1 (CST, #12231), cyclin D1 (CST, #55506), cyclin E1 (CST, #20808), p21 (CST, #2947), p-AKT (CST, #4060), AKT (CST, #9272), p-mTOR (CST, #5536), mTOR (CST, #2983), p-ERK (CST, #4370), and ERK (CST, #4695).

Techniques: Expressing

Mutation portray of BOLA2B across cancers. (A) Differences of BOLA2B mutation type including WT, deletion, and amplification in different cancers. (B) Pie chart of BOLA2B amplification in cancers. (C) Copy number variation (CNV) of BOLA2B indication on the Prognosis Index. (D) Upset plot of possible genes mutation affected BOLA2B expression. (E) Bar chart of microsatellite instability (MSI) relationship with BOLA2B. (F) Tumor stemness of various cancers influenced by BOLA2B expression.

Journal: Frontiers in Genetics

Article Title: Integrative analysis of the role of BOLA2B in human pan-cancer

doi: 10.3389/fgene.2023.1077126

Figure Lengend Snippet: Mutation portray of BOLA2B across cancers. (A) Differences of BOLA2B mutation type including WT, deletion, and amplification in different cancers. (B) Pie chart of BOLA2B amplification in cancers. (C) Copy number variation (CNV) of BOLA2B indication on the Prognosis Index. (D) Upset plot of possible genes mutation affected BOLA2B expression. (E) Bar chart of microsatellite instability (MSI) relationship with BOLA2B. (F) Tumor stemness of various cancers influenced by BOLA2B expression.

Article Snippet: The antibodies used in the study were against BolA2B (Proteintech, # 26080-1-AP), tubulin (Proteintech, #11224-1-AP), CDK6 (Cell Signaling Technology [CST], #13331), cdc6 (CST, #3387), cyclin B1 (CST, #12231), cyclin D1 (CST, #55506), cyclin E1 (CST, #20808), p21 (CST, #2947), p-AKT (CST, #4060), AKT (CST, #9272), p-mTOR (CST, #5536), mTOR (CST, #2983), p-ERK (CST, #4370), and ERK (CST, #4695).

Techniques: Mutagenesis, Amplification, Expressing

GO and KEGG analysis of BOLA2B. (A) BOLA2B possible distribution of cellular components. (B) Enrichment of biological processes that BOLA2B might be involved in. (C) Predicted molecular function of BOLA2B in cancers. (D) KEGG pathway analysis with BOLA2B expression.

Journal: Frontiers in Genetics

Article Title: Integrative analysis of the role of BOLA2B in human pan-cancer

doi: 10.3389/fgene.2023.1077126

Figure Lengend Snippet: GO and KEGG analysis of BOLA2B. (A) BOLA2B possible distribution of cellular components. (B) Enrichment of biological processes that BOLA2B might be involved in. (C) Predicted molecular function of BOLA2B in cancers. (D) KEGG pathway analysis with BOLA2B expression.

Article Snippet: The antibodies used in the study were against BolA2B (Proteintech, # 26080-1-AP), tubulin (Proteintech, #11224-1-AP), CDK6 (Cell Signaling Technology [CST], #13331), cdc6 (CST, #3387), cyclin B1 (CST, #12231), cyclin D1 (CST, #55506), cyclin E1 (CST, #20808), p21 (CST, #2947), p-AKT (CST, #4060), AKT (CST, #9272), p-mTOR (CST, #5536), mTOR (CST, #2983), p-ERK (CST, #4370), and ERK (CST, #4695).

Techniques: Expressing

BOLA2B knockdown reduced breast cancer cell proliferation. (A) Relative mRNA level of BOLA2B knockdown in MDA-MB-231 and SKBR3. (B) Western blot of BOLA2B knockdown in MDA-MB-231 and SKBR3. (C) CCK-8 assay about the BOLA2B-shRNA group downregulated MDA-MB-231, and SKBR3 proliferation compared to the control group. (D) The EdU proliferation assay was performed, and the ratio of EdU-positive cell underwent statistical analysis. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Journal: Frontiers in Genetics

Article Title: Integrative analysis of the role of BOLA2B in human pan-cancer

doi: 10.3389/fgene.2023.1077126

Figure Lengend Snippet: BOLA2B knockdown reduced breast cancer cell proliferation. (A) Relative mRNA level of BOLA2B knockdown in MDA-MB-231 and SKBR3. (B) Western blot of BOLA2B knockdown in MDA-MB-231 and SKBR3. (C) CCK-8 assay about the BOLA2B-shRNA group downregulated MDA-MB-231, and SKBR3 proliferation compared to the control group. (D) The EdU proliferation assay was performed, and the ratio of EdU-positive cell underwent statistical analysis. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: The antibodies used in the study were against BolA2B (Proteintech, # 26080-1-AP), tubulin (Proteintech, #11224-1-AP), CDK6 (Cell Signaling Technology [CST], #13331), cdc6 (CST, #3387), cyclin B1 (CST, #12231), cyclin D1 (CST, #55506), cyclin E1 (CST, #20808), p21 (CST, #2947), p-AKT (CST, #4060), AKT (CST, #9272), p-mTOR (CST, #5536), mTOR (CST, #2983), p-ERK (CST, #4370), and ERK (CST, #4695).

Techniques: Knockdown, Western Blot, CCK-8 Assay, shRNA, Control, Proliferation Assay

BOLA2B knockdown caused cell cycle arrest and downstream pathway. (A) Flow cytometry of cell cycle and statistical histogram of BOLA2B knockdown in MDA-MB-231 and SKBR3. (B) Western blot of related cell cycle marker in MDA-MB-231 and SKBR3. (C) Western blot of downstream pathway markers in MDA-MB-231 and SKBR3. (D) Representative images of IHC staining of BOLA2B in pan-cancer tissues. (E) Statistical histogram of IHC scores in different cancer types. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Journal: Frontiers in Genetics

Article Title: Integrative analysis of the role of BOLA2B in human pan-cancer

doi: 10.3389/fgene.2023.1077126

Figure Lengend Snippet: BOLA2B knockdown caused cell cycle arrest and downstream pathway. (A) Flow cytometry of cell cycle and statistical histogram of BOLA2B knockdown in MDA-MB-231 and SKBR3. (B) Western blot of related cell cycle marker in MDA-MB-231 and SKBR3. (C) Western blot of downstream pathway markers in MDA-MB-231 and SKBR3. (D) Representative images of IHC staining of BOLA2B in pan-cancer tissues. (E) Statistical histogram of IHC scores in different cancer types. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: The antibodies used in the study were against BolA2B (Proteintech, # 26080-1-AP), tubulin (Proteintech, #11224-1-AP), CDK6 (Cell Signaling Technology [CST], #13331), cdc6 (CST, #3387), cyclin B1 (CST, #12231), cyclin D1 (CST, #55506), cyclin E1 (CST, #20808), p21 (CST, #2947), p-AKT (CST, #4060), AKT (CST, #9272), p-mTOR (CST, #5536), mTOR (CST, #2983), p-ERK (CST, #4370), and ERK (CST, #4695).

Techniques: Knockdown, Flow Cytometry, Western Blot, Marker, Immunohistochemistry

Journal: Frontiers in Genetics

Article Title: Integrative analysis of the role of BOLA2B in human pan-cancer

doi: 10.3389/fgene.2023.1077126

Figure Lengend Snippet:

Article Snippet: The antibodies used in the study were against BolA2B (Proteintech, # 26080-1-AP), tubulin (Proteintech, #11224-1-AP), CDK6 (Cell Signaling Technology [CST], #13331), cdc6 (CST, #3387), cyclin B1 (CST, #12231), cyclin D1 (CST, #55506), cyclin E1 (CST, #20808), p21 (CST, #2947), p-AKT (CST, #4060), AKT (CST, #9272), p-mTOR (CST, #5536), mTOR (CST, #2983), p-ERK (CST, #4370), and ERK (CST, #4695).

Techniques: